Skip to content

US · BSEM · BIOTECHNOLOGY

BioStem Technologies, Inc. (BSEM) intrinsic value and stock valuation

$4.74as of 2026-09-18 · Mkt cap 69.29M

Data updated · price as of 2026-09-18

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

BioStem Technologies, Inc. DCF and intrinsic value

InvestorsCraft values BSEM with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from BSEM’s statements →

BioStem Technologies, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Fort Lauderdale, FL, US biostemtechnologies.com

How the business is doing

Fiscal 2025–2010, USD

Revenue
$1.26T+52.8% 5y CAGRd
20252010
Net income
-$-238.28B
20252010
Free cash flow
-$-713.66B
20252010
Total equity
$2.7T+10.4% 5y CAGRd
20252010

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2025–2010, USD
FYFYFYFYFY
Revenue$47.5T$301.8T$16.7T$6.88T$4.34T
Operating income-$-689.15B$31.2T-$-7.78T-$-4.68T-$-1.61T
Net income-$-6.58T$31.9T-$-8.48T-$-7.19T-$-1.45T
EPSd-$-393.39K$1.47M-$-618.88K-$-630.68K-$-155.08K
Operating cash flow$9.94T$24.5T-$-3.5T$303.6B-$-109.44B
Capital expenditure-$-3.35T-$-426.57B-$-210.33B-$-469.48B-$-42.85B
Free cash flow$6.59T$24.1T-$-3.71T-$-165.91B-$-152.29B
Total assets$50T$140.4T$14.6T$3.47T$2.67T
Total debt$3.33T$4.39T$4.72T$5.09T$4.83T
Net debt-$-26.22T-$-18.44T$4.48T$4.32T$4.49T
Total equity$39.1T$40.9T-$-1.34T-$-3.95T-$-5.79T
Cash and short-term investments$29.5T$22.8T$239.4B$772.1B$340.3B
Income statement
FYFYFYFYFY
Revenue$47.5T$301.8T$16.7T$6.88T$4.34T
Cost of revenue$3.26T$13.7T$1.26T$881.8B$1.47T
Gross profit$44.2T$288.1T$15.4T$5.99T$2.87T
Research and development expenses$7.09T$1.91T$342B$224.8B$119.6B
Selling, general and administrative expenses$37.8T$254.7T$22.6T$10.2T$4.19T
Other expenses$0.00$221.3B$229B$243.4B$164.3B
Operating expenses$44.9T$256.9T$23.2T$10.7T$4.47T
Cost and expenses$48.2T$270.6T$24.5T$11.6T$5.95T
Interest income$413.8B$0.00$0.00$0.00$0.00
Interest expense$0.00$587.2B$700.3B$468.2B$525.9B
Depreciation and amortization$219.4B$293.2B$229B$243.4B$283.9B
Ebitda-$-469.73B$31.5T-$-7.55T-$-6.52T-$-602B
Operating income-$-689.15B$31.2T-$-7.78T-$-4.68T-$-1.61T
Total other income/expenses, net$299.5B-$-587.22B-$-704.02B-$-2.55T$193.9B
Income before tax-$-389.65B$30.6T-$-8.48T-$-7.23T-$-1.41T
Income tax expense$6.19T-$-1.27T$0.00$0.00$0.00
Net income-$-6.58T$31.9T-$-8.48T-$-7.19T-$-1.45T
Weighted average shares outstanding$16.7T$16.4T$13.7T$11.4T$9.32T
Weighted average diluted shares outstanding$16.7T$21.7T$13.7T$11.4T$9.32T
Balance sheet
FYFYFYFYFY
Cash and short-term investments$29.5T$22.8T$239.4B$772.1B$340.3B
Net receivables$9.87T$106.2T$11.4T$37.2B$300.1B
Inventory$2.88T$1.82T$658.7B$395.2B$260B
Total current assets$44.4T$133.8T$12.6T$1.49T$938.6B
Property, plant and equipment, net$5.26T$1.97T$1.37T$1.37T$1.28T
Goodwill and intangible assets$364.4B$468.8B$592.2B$607.2B$454.7B
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$5.62T$6.61T$1.96T$1.98T$1.73T
Total assets$50T$140.4T$14.6T$3.47T$2.67T
Accounts payable$4.44T$5.29T$870.2B$570.1B$647.3B
Short-term debt$3.23T$4.06T$4.45T$4.05T$3.03T
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$10.8T$99.2T$15.6T$6.33T$6.54T
Long-term debt$105.3B$330.2B$268.9B$1.04T$1.8T
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$105.3B$330.2B$283.8B$1.09T$1.92T
Capital lease obligations$105.3B$287B$12.3B$20.5B$33.4B
Total liabilities$10.9T$99.5T$15.9T$7.42T$8.47T
Common stock$16.8B$16.7B$16.2B$12.2B$9.74B
Retained earnings-$-21.17T-$-13.74T-$-45.62T-$-37.14T-$-29.95T
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$39.1T$40.9T-$-1.34T-$-3.95T-$-5.79T
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$3.33T$4.39T$4.72T$5.09T$4.83T
Net debt-$-26.22T-$-18.44T$4.48T$4.32T$4.49T
Cash flow statement
FYFYFYFYFY
Net income-$-6.58T$31.9T-$-8.48T-$-7.23T-$-1.41T
Depreciation and amortization$381B$293.2B$229B$222.5B$283.8B
Stock-based compensation$0.00$0.00$5.76T$4.9T$403B
Change in working capital-$-3.98T-$-12.01T-$-2.72T-$-297.56B$515.9B
Accounts receivable$4.43T-$-93.78T-$-11.33T$112.7B-$-288.25B
Inventory-$-1.05T-$-1.17T-$-263.45B-$-135.18B$209.3B
Accounts payable-$-1.5T$4.42T$300.1B-$-77.14B-$-19.49B
Net cash provided by operating activities$9.94T$24.5T-$-3.5T$303.6B-$-109.44B
Investments in property, plant and equipment-$-3.35T-$-426.57B-$-105.33B-$-243.58B-$-42.85B
Acquisitions, net$0.00$0.00$0.00$0.00$35B
Net cash used for investing activities-$-2.1T-$-1.68T-$-210.33B-$-469.48B-$-7.85B
Common stock issued$48.3B$642.6B$0.00$50B$125B
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-1.12T-$-206.78B$3.18T$597.7B$357.4B
Net change in cash$6.72T$22.6T-$-532.73B$431.8B$240.1B
Cash at end of period$29.5T$22.8T$239.4B$772.1B$340.3B
Operating cash flow$9.94T$24.5T-$-3.5T$303.6B-$-109.44B
Capital expenditure-$-3.35T-$-426.57B-$-210.33B-$-469.48B-$-42.85B
Free cash flow$6.59T$24.1T-$-3.71T-$-165.91B-$-152.29B
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About BioStem Technologies, Inc.

        BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.

        CEO
        Jason Matuszewski
        Employees
        73
        Beta
        0.26

        Explore

        Frequently asked questions

        What is the intrinsic value of BioStem Technologies, Inc. (BSEM)?

        InvestorsCraft does not currently publish an intrinsic value for BSEM. How the IC value is calculated.

        Is BSEM undervalued?

        InvestorsCraft does not publish an undervaluation signal for BSEM at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Sep 19, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.